ALDH3A2

Across TCGA pan-cancer cohorts, ALDH3A2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ALDH3A2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ALDH3A2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ALDH3A2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where ALDH3A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.916	0.396	.001	56	view →
PDAC	DFS	Median	All	0.370	0.223	.020	10	view →
GBM	DFS	Quartile	All	0.612	0.949	.003	7	view →
LSCC	OS	Tertile	II,III,IV	0.958	0.692	.018	5	view →
LUAD	DFS	Quartile	II,III,IV	0.686	0.989	.017	1	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ALDH3A2–CCRCC (OS)

Open the CCRCC breakdown →